Clinical Trial Update: Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating redirected autologous T cells engineered with anti-CD19, TCR, and 4-1BB signaling in chemotherapy-resistant or refractory B-cell acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• unlisted autologous T cell therapy with anti-CD19-TCR-4-1BB construct

Snippet

Sponsor: University of Pennsylvania | Conditions: Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options | Phase 2 | Status: COMPLETED | Results posted: 2019-05-24